Active Ingredient History
Lansoprazole is a proton pump inhibitor, which prevents the stomach from producing acid. Lansoprazole has been marketed for many years and is one of several proton-pump inhibitors (PPI's). It was used for the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastrointestinal bleeds with NSAID use. Lansoprazole belongs to a class of ant secretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but that suppress gastric acid secretion by specific inhibition of the (H+, K+ )-ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the parietal cell, lansoprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus. Lansoprazole is extensively metabolized in the liver. Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of lansoprazole). These metabolites have very little or no antisecretory activity. Lansoprazole is thought to be transformed into two active species which inhibit acid secretion by (H+, K+ )-ATPase within the parietal cell canaliculus, but are not present in the systemic circulation. The plasma elimination half-life of lansoprazole does not reflect its duration of suppression of gastric acid secretion. Thus, the plasma elimination half-life is less than two hours, while the acid inhibitory effect lasts more than 24 hours. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Abdominal Pain (Phase 4)
Arrhythmias, Cardiac (Phase 4)
Asthma (Phase 4)
Bacterial Infections (Phase 4)
Bariatric Surgery (Phase 1)
Barrett Esophagus (Phase 4)
Bile Reflux (Phase 4)
Breast Neoplasms (Phase 3)
Coronary Artery Bypass (Phase 4)
Coronary Disease (Phase 4)
Cystic Fibrosis (Phase 1)
Diabetes Mellitus, Type 1 (Phase 3)
Disease Eradication (Phase 4)
Duodenal Ulcer (Phase 3)
Dyspepsia (Phase 4)
Dysphonia (Phase 4)
Endometrial Neoplasms (Phase 2)
Endothelial Cells (Phase 1)
Eosinophilic Esophagitis (Phase 4)
Esophagitis (Phase 4)
Esophagitis, Peptic (Phase 4)
Family (Phase 3)
Gastritis (Phase 4)
Gout (Phase 3)
Healthy Volunteers (Phase 4)
Heartburn (Phase 4)
Heart Diseases (Phase 4)
Helicobacter Infections (Phase 4)
Helicobacter pylori (Phase 4)
Human Experimentation (Phase 3)
Idiopathic Pulmonary Fibrosis (Phase 3)
Infant, Premature (Phase 2)
Infections (Phase 4)
Intestinal Neoplasms (Phase 4)
Kidney Diseases (Phase 2)
Laryngeal Diseases (Phase 4)
Laryngopharyngeal Reflux (Phase 4)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Lymphoma (Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Multiple Endocrine Neoplasia (Phase 4)
Nasal Obstruction (Phase 4)
Nausea (Phase 4)
Neoplasm Metastasis (Phase 1)
Osteoarthritis (Phase 3)
Otitis Media with Effusion (Phase 4)
Pain (Phase 4)
Peptic Ulcer ()
Pharmacokinetics (Phase 1)
Pseudoxanthoma Elasticum (Phase 4)
Psychological Distress (Phase 4)
Purpura (Phase 4)
Respiratory Aspiration (Phase 4)
Respiratory Insufficiency (Phase 4)
Rhinitis (Phase 4)
Stomach Diseases (Phase 4)
Stomach Neoplasms (Phase 3)
Stomach Ulcer (Phase 4)
Tonsillectomy (Phase 4)
Tuberculosis (Phase 3)
Ulcer (Phase 4)
Uterine Cervical Neoplasms (Phase 2)
Uterine Neoplasms (Phase 2)
Zollinger-Ellison Syndrome (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
